Insights on the Heterozygous Familial Hypercholesterolemia Drug Market to 2027 | Industry Statistics, Emerging Demands, Forecast to 2027

The global heterozygous familial hypercholesterolemia drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder. It causes high cholesterol levels that lead to heart disease, heart attack, or stroke. Additionally, HeFH is one form of Familial Hypercholesterolemia (FH). The major factor driving the demand for the heterozygous familial hypercholesterolemia drug is the increasing prevalence of familial hypercholesterolemia across the globe.

According to Medline Plus, familial hypercholesterolemia affects an estimated 1 in 200 to 1 in 250 people in most countries. Additionally, it is the most common inherited condition affecting the heart and blood vessels. Furthermore, the condition occurs more frequently in certain populations that include Afrikaners in South Africa, Lebanese, and Tunisians. Hence, the increasing prevalence of familial hypercholesterolemia is driving the demand for heterozygous familial hypercholesterolemia drugs for treatment which in turn is driving the growth of the market.

To Request a Sample of our Report on Heterozygous Familial Hypercholesterolemia Drug Market: https://www.omrglobal.com/request-sample/heterozygous-familial-hypercholesterolemia-drug-market

Some major players in the market include Sanofi SA, Amgen Inc., and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2021, Amgen announced the approval of Repatha (evolocumab) from the US Food and Drug Administration (FDA). It is used as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering therapies for the treatment of heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 10 years and older.

Market Coverage

· The market number available for - 2020-2027

· Base year- 2020

· Forecast period- 2021-2027

Segment Covered-

· By Product Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Sanofi SA, Amgen Inc., and Novartis International AG, among others.

(Get 15% Discount on Buying this Report)

A full Report of Heterozygous Familial Hypercholesterolemia Drug Market is Available @ https://www.omrglobal.com/industry-reports/heterozygous-familial-hypercholesterolemia-drug-market

Global Heterozygous Familial Hypercholesterolemia Drug Market Report by Segment

By Type

• Gemcabene Calcium

• MGL-3196

• ST-103

• Others

By Application

• Hospital

• Medical Center

• Clinics

• Others

Global Heterozygous Familial Hypercholesterolemia Drug Market Report by Region



Regional Analysis

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.